Semaglutide vs Sitagliptin
This study is for people who have had a liver transplant and also have type 2 diabetes that isn't well-controlled. Researchers want to compare two different medicines, Semaglutide and Sitagliptin, to see which one works better at controlling blood sugar and helping with body weight. They'll also check for any side effects. Participants will take one of these medicines daily for about 6 months, while continuing their usual diabetes medication. This research helps us understand the best ways to manage diabetes after a liver transplant, which is important for long-term health.
At a glance
What is this study about?
This study is looking into which diabetes medicine might be best for people who have had a liver transplant. When someone has a liver transplant, they can sometimes develop diabetes, or find their existing diabetes harder to control. This is a common issue, and doctors want to find the safest and most effective ways to help.
The study will compare two medicines: Semaglutide and Sitagliptin. Both are used to help manage type 2 diabetes. The goal is to see how well each medicine helps to keep blood sugar levels stable, if they help with body weight, and if they have any side effects specifically in people who've had a liver transplant. Understanding these effects is vital because people who've had transplants often take other medications that can interact.
This type of study, called a 'Phase 4' trial, means that both medicines are already approved for use in diabetes. The study aims to gather more information about their use in a specific group of people – those with liver transplants – and to compare them directly. This helps doctors make better choices about what to prescribe for their patients in the future.
Key takeaways
- Compares two diabetes medicines in liver transplant recipients.
- Aims to improve blood sugar control and body weight.
- Involves a daily pill for approximately 6 months.
- Requires regular clinic visits for checks and samples.
- Both medicines are already used for diabetes treatment.
- Helps doctors learn the best care for diabetes after a liver transplant.
Who may be eligible?
You might be able to take part in this study if you are 18 years or older and have had a liver transplant (or a liver and kidney transplant). It's important that your transplant happened at least 3 months ago and there are no signs of your body rejecting the new liver at the moment. You also need to have type 2 diabetes or diabetes that started after your transplant, and your blood sugar levels (measured by an HbA1c test) should be between 6.5% and 10.5%, meaning your diabetes isn't perfectly controlled right now.
Even if you're taking other diabetes medicines like insulin, metformin, or SGLT2 inhibitors, you might still be able to join, as long as your doses have been stable recently. Your liver enzymes should generally be normal, but if they are slightly high because of fatty liver disease (NASH) that's been confirmed by a liver biopsy, you might still be considered. You also need to be able to understand the study and agree to take part.
However, you won't be able to join if you're allergic to the study medications, if you're currently having strong steroid treatment for liver rejection, or if you've been transplanted for certain genetic conditions like amyloidosis or cystic fibrosis. If you are pregnant, breastfeeding, or planning to become pregnant, you also can't take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years or older?
- Have you had a liver transplant at least 3 months ago?
- Do you have type 2 diabetes or diabetes after your transplant?
- Is your diabetes not perfectly controlled (HbA1c between 6.5% and 10.5%)?
- Are you not currently pregnant or breastfeeding?
- Are you not allergic to diabetes medicines?
What does participation involve?
If you join this study, you'll be randomly put into one of two groups: one group will receive the medicine Semaglutide, and the other will receive Sitagliptin. You'll take one of these medicines once a day. You'll also continue taking any other diabetes medications you're already on, like metformin or insulin, at their usual doses. The treatment with the study medicine will last for 26 weeks, which is about six months.
Throughout the study, you'll have several visits to the clinic. These visits will involve checks of your blood sugar levels and body weight. The team will also take blood and stool samples to understand how the medicines might affect your body and gut health. At the start and end of the study, you'll also have a special scan called a Transient Elastography to check for any changes in liver fat. There will be a screening period to make sure you're suitable, a treatment period, and a follow-up period after you finish the medicine. The research team will explain the full schedule of visits and what each involves.
Potential risks and benefits
Locations (1)
- Toronto General HospitalVerified postcodeToronto, Canada
Common questions
What is an HbA1c test?
An HbA1c test measures your average blood sugar levels over the past 2-3 months. It's a common test to assess how well your diabetes is being managed.
What is Transient Elastography?
This is a special scan, similar to an ultrasound, that helps doctors check the stiffness and fat content of your liver without needing a biopsy.
Will I know which medicine I'm getting?
No, this is a 'double-blind' study, meaning neither you nor the doctors will know whether you are taking Semaglutide or Sitagliptin. This helps make the study results fair.
Do I have to stop my other diabetes medicines?
No, you will continue with your usual diabetes medicines like metformin or insulin, but it's important that your doses have been stable before the study starts.
How long will the study last for me?
The main treatment part of the study will last for 26 weeks (about 6 months), but there will also be initial screening and follow-up visits.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.